Deoxycytidine kinase (dCK), a rate-limiting enzyme in the cytosolic deoxyribonucleoside (dN) salvage pathway, is an important therapeutic and positron emission tomography (PET) imaging target in cancer. PET probes for dCK have been developed and are effective in mice but have suboptimal specificity and sensitivity in humans. To identify a more suitable probe for clinical dCK PET imaging, we compared the selectivity of two candidate compounds-[ 18 F]Clofarabine; 2-chloro-2′-deoxy-2′-[ 18 F]fluoro-9-β-D-arabinofuranosyl-adenine ([ 18 F]CFA) and 2′-deoxy-2′-[ 18 F]fluoro-9-β-D-arabinofuranosylguanine ([ 18 F]F-AraG)-for dCK and deoxyguanosine kinase (dGK), a dCK-related mitochondrial enzyme. We demonstrate that, in the tracer concentration range used for PET imaging, [ 18 F]CFA is primarily a substrate for dCK, with minimal cross-reactivity. In contrast, [ 18 F]F-AraG is a better substrate for dGK than for dCK. [ 18 F]CFA accumulation in leukemia cells correlated with dCK expression and was abrogated by treatment with a dCK inhibitor. Although [ 18 F]CFA uptake was reduced by deoxycytidine (dC) competition, this inhibition required high dC concentrations present in murine, but not human, plasma. Expression of cytidine deaminase, a dC-catabolizing enzyme, in leukemia cells both in cell culture and in mice reduced the competition between dC and [ 18 F]CFA, leading to increased dCK-dependent probe accumulation. First-in-human, to our knowledge, [ 18 F]CFA PET/CT studies showed probe accumulation in tissues with high dCK expression: e.g., hematopoietic bone marrow and secondary lymphoid organs. The selectivity of [ 18 F]CFA for dCK and its favorable biodistribution in humans justify further studies to validate [ 18 F]CFA PET as a new cancer biomarker for treatment stratification and monitoring.
nucleotide metabolism | deoxycytidine kinase | PET imaging | cancer A ccurate DNA replication and repair require sufficient and balanced production of deoxyribonucleoside triphosphates (dNTPs) (1) . Mammalian cells synthesize dNTPs by two biochemical routes: the de novo pathway produces dNTPs from glucose and amino acid precursors whereas the nucleoside salvage pathway generates dNTPs from deoxyribonucleosides (dNs) scavenged from the extracellular milieu by the combined action of nucleoside transporters and dN kinases (Fig. S1A) . The cytosolic dN kinases in mammalian cells are thymidine kinase 1 (TK1), which phosphorylates thymidine (dT) and deoxyuridine (dU), and deoxycytidine kinase (dCK), which phosphorylates deoxycytidine (dC), deoxyadenosine (dA), and deoxyguanosine (dG) (2) . Although dCK has been studied extensively in vitro, its in vivo functions are not well understood. Previously, we reported impaired hematopoiesis in dCK −/− mice resulting from DNA replication stress in hematopoietic progenitors due to insufficient dCTP supply (3, 4) . More recently, we showed that, in cancer cells, dCK confers resistance to inhibitors of de novo dCTP biosynthesis and that pharmacological cotargeting of dCK and ribonucleotide reductase, the rate-limiting enzyme in the de novo pathway, was well-tolerated and efficacious in animal models of acute leukemia (5, 6) . dCK also plays an essential role in the activation of the nucleoside analog prodrugs Cytarabine, Fludarabine, Gemcitabine, Decitabine, Cladribine, and Clofarabine (7) ( Fig. S1B ). Clinically applicable assays to measure tumor dCK activity in vivo would be of great value, given the variable response rates and toxicities associated with these frequently used prodrugs (7) . Collectively, the identification of dCK as a new therapeutic target in acute Significance Deoxycytidine kinase (dCK) is required for the activation of multiple nucleoside analog prodrugs used in cancer therapy and is a potential new therapeutic target in hematological malignancies. Here, we identify [ 18 F]Clofarabine; 2-chloro-2′deoxy-2′-[ 18 F]fluoro-9-β-D-arabinofuranosyl-adenine ([ 18 F]CFA) as a new candidate PET probe for dCK, with superior specificity and biodistribution in humans compared with existing probes. [ 18 F]CFA PET may provide a useful companion biomarker for therapeutic interventions against cancer that include nucleoside analog prodrugs, dCK inhibitors, and immunotherapies. leukemia, the requirement for dCK in the activation of FDAapproved nucleoside analog prodrugs, and the heterogeneous expression of dCK in cancer suggest that dCK is an important target for noninvasive biomarker PET imaging.
The first PET probe described for dCK imaging was 1-(2′deoxy-2′-[ 18 F]fluoro-β-D-arabinofuranosyl)cytosine ([ 18 F]FAC) (8) . Although [ 18 F]FAC enabled PET imaging of dCK activity in mice (8) (9) (10) (11) , a subsequent study (12) questioned its clinical utility because of rapid probe catabolism mediated by cytidine deaminase (CDA), an enzyme present at higher levels in humans than in rodents (13) . CDA converts [ 18 F]FAC to 1-(2′-deoxy-2′-[ 18 F]fluoro-β-D-arabinofuranosyl)uracil ([ 18 F]FAU), a metabolite that is not phosphorylated by dCK. To overcome this problem, L-enantiomer analogs of [ 18 F]FAC that resisted deamination and retained affinity for dCK were developed (14) . Two of the L-enantiomer analogs-1-(2′-deoxy-2′-[ 18 F]fluoro-β-L-arabinofuranosyl)cytosine (L-[ 18 F]FAC) and 2′-deoxy-2′-[ 18 F]fluoro-5-methyl-β-L-arabinofuranosylcytosine (L-[ 18 F]FMAC)-were translated to the clinic (12, 15) . These second generation dCK probes had better sensitivity than [ 18 F]FAC in humans as reflected by improved accumulation in the bone marrow, a tissue with high dCK activity. However, both L-FAC analogs were cross-reactive with mitochondrial thymidine kinase 2 (TK2), which, like dCK, lacks enantioselectivity and consequently phosphorylates deoxypyrimidines with both D-and L-enantiomeric configurations (16) . In humans, cross-reactivity with TK2 was likely responsible for the uptake of the FAC analogs into the myocardium (12), a tissue with high TK2 expression (17) .
Because dCK phosphorylates both pyrimidines and purines (18) , the limitations of current PET probes for dCK could be circumvented using fluorinated purine analogs. Two candidate purine PET probes for dCK have been proposed ( Fig. 1A) : (19) . Unlike FAC and its analogs, neither of these purine analogs is phosphorylated by TK2. However, both [ 18 F]CFA and [ 18 F]F-AraG may be substrates for the mitochondrial deoxyguanosine kinase (dGK) ( Fig. 1A) , which is structurally related to both dCK and TK2 (20) . Despite some overlap in substrate specificity, dCK and dGK have distinct biological functions (18, 21, 22) and expression patterns (22, 23) . Therefore, to properly interpret the information provided by [ 18 F]CFA and [ 18 F]F-AraG PET scans, it is essential to delineate the roles played by dCK and dGK in the intracellular trapping of these two candidate PET probes. Here, we compared the selectivity of [ 18 F]CFA and [ 18 F]F-AraG for dCK and dGK. Observed differences in kinase selectivity indicated that PET assays using these probes are likely to have distinct applications, with [ 18 F]CFA as the choice for clinical dCK imaging and [ 18 F]F-AraG as the appropriate probe for dGK imaging. We then investigated whether competition between [ 18 F]CFA and endogenous dC affected the sensitivity of [ 18 F]CFA PET imaging in the range of plasma dC concentrations found in mice, humans, and other species. We also present preliminary first-in-human, to our knowledge, studies of [ 18 F]CFA biodistribution and discuss how this tracer complements the current repertoire of PET probes for nucleotide metabolism.
Results

Differential Selectivity of [ 18 F]CFA and [ 18 F]F-AraG for dCK and dGK.
To determine the selectivity of [ 18 F]CFA and [ 18 F]F-AraG for dCK and dGK, CEM-R leukemia cells, which do not express dCK (24) but contain endogenous dGK ( Fig. 1B) , were reconstituted with human dCK (CEM-R-dCK) ( Fig. 1B) . To enable an additional comparison between [ 18 F]CFA and [ 18 F]F-AraG in the absence of any confounding aspects related to potential differences in the access of these two probes to mitochondriallocated dGK, we also generated CEM-R cells that express a (Fig. 1C ). DI-82, a specific dCK inhibitor (25) , abrogated [ 3 H]dC accumulation in CEM-R-dCK cells (Fig. 1C ). CEM-R-ΔdGK cells retained 6.62 ± 0.49-fold more [ 3 H]dG compared with CEM-R-EYFP cells (Fig. 1D) , thereby confirming the functionality of the truncated dGK construct. [ 3 H]dG also accumulated in CEM-R-dCK cells (2.01 ± 0.19-fold increase relative to CEM-R-EYFP cells) ( Fig. 1D) , consistent with the ability of dCK to phosphorylate both pyrimidine and purine substrates (2, 18) . The isogenic CEM-R panel was then used to compare the accumulation of tracer amounts (50- (27, 28) . As shown in Fig. 2A, [ 3 H]CFA accumulation is also inhibited in a dosedependent manner by dC, the physiological substrate of dCK, with an IC 50 value of 181 ± 56 nM ( Fig. 2A) . Deoxyadenosine (dA) and deoxyguanosine (dG), which are also dCK substrates (18) , also inhibited [ 3 H]CFA accumulation (Fig. S2 ). The high IC 50 values observed for dA and dG (75 μM and 33 μM, respectively) ( Fig. S2 ) likely reflect the rapid catabolism of these purine dNs by adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP); both are expressed at high levels in lymphoid cells (29, 30) .
To determine whether the competition between CFA and dC observed in cell culture could also occur in vivo, plasma dC levels in humans, nonhuman primates (NHPs), mice, and rats were measured by combined liquid chromatography tandem mass spectrometry in the multiple reaction-monitoring mode (LC-MS/ MS-MRM) (Fig. 2B ). C57BL/6 mouse and rat plasma dC concentrations were in the high nanomolar to low micromolar range, which, according to our cell culture data, are sufficient to inhibit CFA uptake. In marked contrast, plasma dC concentrations were two to three orders of magnitude lower in humans and NHPs than in mice and rats and are well-below the levels that can inhibit CFA uptake. A similar pattern was observed for dT in our study (Fig. 2C ), in agreement with previous reports (31, 32) . In contrast to dC and dT, plasma concentrations of dA and dG did not differ significantly in the examined species ( Fig. 2 D and E) . Mouse plasma dN levels were not affected by 24-h fasting (Fig.  2F) , arguing against an exogenous origin for these nucleosides. Instead, the observed differences are likely the result of different catabolic rates of endogenously produced dC and dT in rodents vs. primates. To test this hypothesis, stable isotope-labeled dC ([U-13 C 9 , 15 N 3 ]dC) was incubated for 1 h in human and mouse plasma samples with or without tetrahydrouridine (THU), a specific cytidine deaminase (CDA) inhibitor (33) . CDA catalyzes the first step in dC catabolism by converting dC to deoxyuridine (dU). LC-MS/MS-MRM analyses of labeled dC and dU demonstrated that dC was catabolized more rapidly in human than in murine plasma (Fig. 2G, Top and Bottom) . Moreover, the CDA inhibitor THU blocked dC deamination in human plasma (Fig. 2G, Middle) .
To further investigate how CDA expression influences CFA accumulation, CEM cells engineered to express CDA (CEM-CDA) or EYFP (CEM-EYFP, negative control) (Fig. 3A) were incubated with cell culture medium containing 5 μM [U-13 C 9 , 15 N 3 ]dC. The medium was sampled at the times shown to measure the CDA-mediated catabolism of labeled dC. An ∼32-fold decrease in the amount of [U-13 C 9 , 15 N 3 ]dC was observed after a 6 h incubation with CEM-CDA cells, but not with the CDA-negative cells (Fig. 3B ). Consequently, [ 3 H]CFA added for 1 h after the 6-h incubation period was retained only in the CEM-CDA cells.
[ 3 H]CFA accumulation by the CEM-CDA cells was dCKdependent, as indicated by the effect of the dCK inhibitor DI-82 ( Fig. 3C) . To model these cell culture findings in vivo, nonobese diabetic (NOD) SCID IL-2 receptor gamma chain KO (NSG) mice underwent s.c. bilateral implantation with either CEM-EYFP or CEM-CDA cells in both flanks. Mice bearing bilateral tumors were imaged serially by PET/CT, using either [ 18 F]CFA or [ 18 F]FDG, at the indicated times (Fig. 4A) . Plasma dC concentrations decreased with time in mice with CEM-CDA tumors but not in mice with CEM-EYFP tumors (Fig. 4B) , likely reflecting the leakage of tumor CDA in plasma. Consistent with the cell culture data (Fig. 3C) , mice bearing CEM-CDA tumors, which had reduced plasma dC levels, accumulated significantly more [ 18 F]CFA than mice bearing CEM-EYFP tumors, as indicated by day 17 PET scans ( Fig. 4 C and D) . [ 18 F]FDG PET scans performed on day 18 revealed similar metabolic activity in both CDA and EYFP tumors ( Fig. 4 C and E) . On day 19, mice were treated with DI-82 followed by a second [ 18 F]CFA PET scan, which confirmed that tumor probe accumulation was dCKdependent ( Fig. 4 C and D) First-in-Human [ 18 F]CFA Biodistribution Studies. Because dC competes with CFA for cellular uptake ( Fig. 2A) and because plasma dC levels are two to three orders of magnitude lower in humans than in mice (Fig. 2B) , we hypothesized that the biodistribution of [ 18 F]CFA will be more favorable in humans than in mice. Indeed, unlike the negative scans in mice (14) region corresponds anatomically to the part of the vertebral column that was previously (9 mo before the scan) irradiated to target a tumor lesion at this location. This serendipitous finding suggested that [ 18 F]CFA bone accumulation in humans likely reflects dCK-dependent probe uptake by bone marrow cells, rather than probe defluorination. Further supporting this interpretation, CFA defluorination was not detected in metabolic stability studies of CFA administered at pharmacological doses in humans (34) .
Discussion
We show that [ 18 F]CFA is a highly specific substrate/probe for dCK, with minimal cross-reactivity with dGK. [ 18 F]CFA accumulation in leukemia cells was competitively inhibited in a concentrationdependent manner by dC, the physiological dCK substrate. Evidence is provided that plasma dC levels vary significantly across species and that these variations correspond to striking differences in [ 18 F]CFA biodistribution between mice and humans. Accordingly, the [ 18 F]CFA PET assay is more sensitive in humans than in mice, due to reduced competition between the probe and endogenous dC. [ 18 F]CFA accumulation in leukemia cells was dCK-dependent, and probe accumulation was sensitive to variations in dCK expression. In this context, a large variation in dCK expression and activity was observed in a panel of lymphoma cell lines (35) . Similar variations in dCK expression likely occur in other cancers. dCK mRNA levels also increase upon T-cell activation (8) . Additional levels of dCK regulation involve posttranslational mechanisms. For example, phosphorylation of dCK at Ser-74 increases dCK activity (36) . The DNA-damage response kinase Ataxia-telangiectasia mutated (ATM) has been proposed to catalyze this dCK phosphorylation (36) (37) (38) . If the observed sensitivity of [ 18 F]CFA PET to variations in dCK activity is confirmed by larger clinical studies, this noninvasive, real-time PET assay may provide a useful biomarker for various therapies that trigger T-cell activation, induce DNA damage (36) , or rely on dCK-dependent nucleoside analog prodrugs. In particular, [ 18 F]CFA may be useful as a pharmacokinetic PET stratification biomarker for its corresponding drug Clofarabine (Clolar; Genzyme) (39) . Furthermore, as dCK inhibitors (5, 6, 25) advance toward clinical trials, [ 18 F]CFA PET could provide a companion pharmacodynamic biomarker to help optimize dosing and scheduling regimes. Given the susceptibility of [ 18 F]CFA uptake to competition by endogenous nucleosides, the use of [ 18 F]CFA in patients with elevated plasma dN levels may result in false-negative scans. Such conditions include the tumor lysis syndrome that follows chemotherapy in hematological malignancies (40) , genetic defects in the purine nucleoside-catabolizing enzymes adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) (41, 42) , and treatment of certain leukemias with ADA and PNP inhibitors (43, 44) . In addition to plasma dN levels, which should be determined in each patient scanned with [ 18 F]CFA, the interpretation of [ 18 F]CFA PET scans should also take into account factors other than dCK that could modulate probe accumulation. Both concentrative and equilibrative nucleoside transporters, as well as ATP-binding cassette (ABC) transporters, could all modulate [ 18 F]CFA accumulation in tumors (45, 46) .
In summary, this work supports the evaluation of [ 18 F]CFA in larger clinical studies as a companion biomarker for multiple therapeutic approaches. Moreover, [ 18 F]CFA complements the toolbox of nucleoside analog PET probes for imaging dN kinases (Fig. 6) . Given the diverse biological functions and the therapeutic relevance of cytosolic and mitochondrial dN kinases, the availability of a toolbox of PET imaging probes to noninvasively measure the activity of these enzymes could enable a wide range of preclinical and clinical applications. Immunoblotting. Immunoblotting was performed as previously described (4) . Primary and secondary antibodies are provided in SI Materials and Methods. Cell-Based Uptake Assays Using Radioactive Probes. Uptake assays were conducted as previously described (47) . See details in SI Materials and Methods. (50, 51) . Potential applications for these probes, as well as anatomical sites of preferential accumulation in healthy volunteers, are indicated. *, [ 18 F]FLT accumulation in the liver reflects probe glucuronidation (52) . N.D., not determined; PD, pharmacodynamic; PK, pharmacokinetic. **, [ 18 F]F-AraG uptake may also reflect dCK activity.
Materials and Methods
MicroPET/CT and PET/CT Studies. MicroPET/CT experiments were conducted as previously described (14) . Briefly, prewarmed and anesthetized NSG mice were injected with indicated probes, and PET and CT images were acquired using the G8 PET/CT scanner (Sofie Biosciences) 3 h after the injection of 740 kBq of [ 18 F]CFA. Clinical PET/CT studies were performed under a Radioactive Drug Research Committee protocol and under the approval from UCLA Institutional Review Boards as previously described (12) . Briefly, 233.1 MBq of [ 18 F]CFA was injected in the clinical subjects. For the healthy volunteer, dynamic imaging was performed immediately after the probe injection. For the paraganglioma patient, static imaging was performed 35 min after the probe injection.
Additional Information. Additional experimental details are described in SI Materials and Methods.
